The new sample-to-answer platform supports continuous loading and automated workflows for clinical laboratories.
Bruker announced the European launch of MyGenius PRO, a fully automated, sample-to-answer molecular diagnostics system, during the European Society of Clinical Microbiology and Infectious Diseases Global 2026 meeting.
The system uses polymerase chain reaction technology for infectious disease diagnostics. Designed for higher throughput, the platform supports random-access operation and the continuous loading of samples, consumables, and reagents. The system automates the entire workflow from patient sample to diagnostic result to help clinical laboratories manage high testing volumes.
Initial Assay Menu and Expansion
At launch, the MyGenius PRO In Vitro Diagnostic Regulation menu includes assays for cytomegalovirus and Epstein-Barr virus using whole blood, and BK virus using urine. These initial offerings are intended to support diagnostic testing for immunocompromised patients.
[Bruker] plans to expand the assay menu throughout 2026. Planned additions include IVDR assays for Human Immunodeficiency Virus type 1, Hepatitis B virus, Hepatitis C virus, and Human Herpesvirus 6, along with support for additional sample matrices.
Strategic Collaborations
The platform was developed through a collaboration between ELITechGroup, a Bruker company, and Hitachi High-Tech Corporation. This partnership combined expertise in molecular assays with automation and engineering. In Japan, Hitachi High-Tech will introduce the system under the name LABOSPECT GA-5, which will include Bruker molecular diagnostic assays for infectious disease testing.
“Timely diagnosis is critical in microbiology and virology. Fully automated sample-to-result solutions improve turnaround time and support faster clinical response and effective infection monitoring, while enabling laboratories to streamline workflows and ensure compliance with IVDR regulations,” says Dr Pierangelo Clerici, president of the Italian Association of Clinical Microbiologists, in a release.
The introduction of the platform expands the company’s microbiology and infection diagnostics portfolio. This collection includes the InGenius and BeGenius systems, a growing CE-IVD assay menu, and LiquidArray assays designed for multiplexing and syndromic panel testing.
Photo caption: MyGeniusPRO
Photo credit: Bruker
